Acomplia and Steven Nissen

The rejection of Acomplia doesn’t make crusader Steven Nissen look good:

That means it’s at least the second time in under a year that Steven Nissen has been wrong about the promise of new drugs. Nissen, of course, is the well-known Cleveland Clinic cardiologist whose efforts were largely responsible for toppling Vioxx, and he just co-authored a NEJM study raising serious doubts about Avandia.

He was also optimistic about Pfizer-dud torcetrapib. (via WSJ Health Blog)

Related posts:

1. Conflict of interest and Steven Nissen, the next potental head of the FDA
2. RIP Torcetrapib
3. Is the pressure getting to Steven Nissen?
4. Did the Avandia scare harm patients, and is Steven Nissen to blame?
5. Taking Steven Nissen to task
6. Nissen pumps up Actos
7. Nissen angling for the FDA?

  Follow on Twitter   Subscribe

Tagged as: drugs